Friday 23 October 2026
Export PCSA’s income statement to Excel — free account
Heatwurx Inc.
PCSA Healthcare Biotechnology
In the quarter to June 2026, EPS grew 81.0% and free cash flow grew 20.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.89
0.03
+1.61%
Follow PCSA
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Price, $ | |||||||||||||||||
| Price, $ | Low | 3,675.00 | 1,680.00 | 5,250.00 | 4,690.00 | 1,700.00 | 1,927.50 | 505.00 | 90.00 | 20.30 | 2.75 | (55.1%) | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | |
| High | 9,800.00 | 17,885.00 | 17,937.50 | 12,775.00 | 9,000.00 | 7,120.00 | 2,630.00 | 725.00 | 185.00 | 27.00 | (48.1%) | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ||
| People | |||||||||||||||||
| People | Employees | 1 | 13 | 15 | 13 | 14 | 15 | 15 | 13 | 10 | 12 | +31.8% | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | |
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ||
| Income, $m | |||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | 40 | — | — | — | |
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.0 pt | ||||||
| EBT | (2) | (2) | (5) | (4) | (15) | (12) | (27) | (11) | (12) | (14) | +24.3% | ||||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | (2) | (2) | (4) | (3) | (14) | (11) | (27) | (11) | (12) | (14) | +24.3% | ||||||
| Depreciation | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | (1.7%) | ||||||
| Per share, $ | |||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | (228.93) | (210.08) | (350.14) | (350.00) | (960.92) | (375.00) | (850.00) | (212.00) | (96.75) | (10.36) | (29.1%) | ||||||
| Cash flow | (256.55) | (177.91) | (346.53) | (247.76) | (209.55) | (284.88) | (298.29) | (153.59) | (91.87) | (8.70) | (31.3%) | ||||||
| Capex | (2.83) | (2.22) | (2.08) | 0.00 | 0.00 | 0.00 | 0.00 | (0.05) | (0.03) | (0.65) | (15.1%) | ||||||
| Free cash flow | (259.38) | (180.13) | (348.62) | (247.76) | (209.55) | (284.88) | (298.29) | (153.64) | (91.90) | (9.35) | (30.9%) | ||||||
| Book value | 269.90 | 40.13 | 906.64 | 721.86 | 1,529.30 | 832.85 | 232.01 | 95.03 | 13.86 | 4.26 | (36.9%) | ||||||
| Shares, m | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | +75.2% | ||||||
| Valuation, × | |||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Cash, $m | |||||||||||||||||
| Cash, $m | Operating cash flow | (2) | (2) | (4) | (3) | (3) | (9) | (10) | (8) | (11) | (11) | +20.3% | |||||
| Capex | 0 | 0 | 0 | — | — | — | — | 0 | 0 | (1) | +48.8% | ||||||
| Free cash flow | (2) | (2) | (4) | (3) | (3) | (9) | (10) | (8) | (11) | (12) | +21.1% | ||||||
| Balance, $m | |||||||||||||||||
| Balance, $m | Working capital | 2 | 0 | 1 | 0 | 15 | 17 | 7 | 5 | 0 | 3 | +4.9% | |||||
| Total debt | — | 2 | 0 | 1 | 0 | 0 | 0 | — | — | — | (37.7%) | ||||||
| Net debt | (2) | 0 | (2) | 0 | (15) | (16) | (7) | (5) | (1) | (6) | +11.4% | ||||||
| Shareholders’ equity | 2 | 0 | 10 | 8 | 23 | 25 | 7 | 5 | 2 | 6 | +10.5% | ||||||
| Returns, % | |||||||||||||||||
| Returns, % | ROA | (155.28) | (69.42) | (48.69) | (33.08) | (79.86) | (44.23) | (156.34) | (154.40) | (262.87) | (245.66) | (90.4) pt | |||||
| ROIC | (682.35) | 0.00 | (34.53) | (29.74) | (125.00) | (84.38) | (1,309.15) | (2,530.28) | (1,491.78) | (21,694.32) | (21,012.0) pt | ||||||
| ROE | (1,329.47) | (140.61) | (74.75) | (43.64) | (93.14) | (47.20) | (166.43) | (178.52) | (354.51) | (372.96) | +956.5 pt | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2015 · latest quarter Mar 2016
Earnings Trends EPS, adjusted, against the consensus
Q1 FY26 Estimate −1.00 Actual −1.29
| Quarter | Estimate | Reported | Result |
|---|---|---|---|
| Q1 FY25 | −19.25 | −7.50 | Beat by 11.75 |
| Q2 FY25 | −5.75 | −6.25 | Miss by 0.50 |
| Q3 FY25 | −2.00 | −1.75 | Beat by 0.25 |
| Q1 FY26 | −1.00 | −1.29 | Miss by 0.29 |
Charts ten years each
Heatwurx Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| PCSA Heatwurx Inc. | $5.2M | 1.8× | — | −64.29% (below 0%: shrinking) | n/m | +20.29% (above 0%: growing) | 0.00% | 0.00% | |
| CELZ Creative Medical Technology Holdings, Inc. | $5.1M | — (loss-making) | — (loss-making) | 0.00% | n/m | −27.05% (below 0%: shrinking) | 66.67% | 0.00% | Compare |
| LGVN Longeveron Inc. | $5.1M | — (loss-making) | — (loss-making) | −9.18% (below 0%: shrinking) | n/m | −49.12% (below 0%: shrinking) | 63.41% | (2,150.17%) | Compare |
| CDIO Cardio Diagnostics Holdings, Inc. | $5.1M | — (loss-making) | — (loss-making) | −28.00% (below 0%: shrinking) | n/m | +15.58% (above 0%: growing) | 100.00% | (27,742.59%) | Compare |
| RVPH Reviva Pharmaceuticals Holdings, Inc. | $5.0M | — (loss-making) | — | — | n/m | +57.80% (above 0%: growing) | — | 0.00% | Compare |
| NRSN NeuroSense Therapeutics Ltd. | $4.6M | — (loss-making) | — | — | n/m | −23,458.82% (below 0%: shrinking) | — | 0.00% | Compare |
| XBIO Xenetic Biosciences, Inc. | $4.5M | — (loss-making) | — (loss-making) | +11.99% (above 0%: growing) | n/m | −128.11% (below 0%: shrinking) | 100.00% | (147.09%) | Compare |
| ADTX Aditxt, Inc. | $4.4M | — (loss-making) | — | +1,120.00% (above 0%: growing) | n/m | +60.82% (above 0%: growing) | 23.77% | (35,753.28%) | Compare |
| JAGX Jaguar Animal Health, Inc. | $4.2M | 0.0× | — (loss-making) | −58.88% (below 0%: shrinking) | n/m | +13.83% (above 0%: growing) | 15.84% | (620.16%) | Compare |
| Median of peers | $4.8M | — | — | −4.59% | — | −6.61% | 65.04% | (383.62%) |
Heatwurx Inc. (PCSA) key facts
- Heatwurx Inc. (PCSA) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 23, 2026, PCSA traded at $1.90, a market capitalization of $5.2 million.
- Return on equity was −373.0% and debt-to-equity 0.00.